ClinicalTrials.gg
RecruitingNCT06057948Updated Nov 9, 2026

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

A Phase 2 interventional study of OPT-821 (QS-21) and oral β-glucan in Neuroblastoma, High-risk Neuroblastoma and Metastatic Neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in United States. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.
Updated Oct 14, 2026Enrollment updatedEligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Neuroblastoma by Memorial Sloan Kettering Cancer Center — 5 open to participants now, 10 under way, none of them phase 3. Neuroblastoma · Memorial Sloan Kettering Cancer Center.

Planned enrollment
6th of 37
100 · median 45
Started
2023
with 1 other
Phase 2
22 of 51
4 open now
Registered
49th of 51
by date

Among the 51 studies in Neuroblastoma by Memorial Sloan Kettering Cancer Center, this one is the 6th largest by planned enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2023, is one of 22 in phase 2, and was the 49th registered.

Neuroblastoma

676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.

Browse Neuroblastoma studies →

Open to participants now

5 of the 51 studies in Neuroblastoma by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Neuroblastoma by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The purpose of this study is to test which treatment schedule of β-glucan with bivalent vaccine is more effective for participants with high-risk neuroblastoma that is in complete remission.

03

Conditions studied

  • Neuroblastoma
  • High-risk Neuroblastoma
  • Metastatic Neuroblastoma

Browse trials for

Keywords

  • Neuroblastoma
  • High-risk Neuroblastoma
  • Metastatic Neuroblastoma
  • HR-NB
  • Memorial Sloan Kettering Cancer Center
  • 23-198
04

Who can participate

The criteria were revised on the registry on Oct 14, 2026. See what changed

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of NB as defined by international criteria,102 i.e., histopathology (confirmed by the MSK Department of Pathology) or BM plus high urine catecholamine levels, or positivity in MIBG scan.
  • HR-NB as defined by risk-related treatment guidelines and international criteria,102 i.e., metastatic/non-localized disease with MYCN amplification (any age), metastatic disease >18 months old, MYCN-amplified localized disease (any age), or disease resistant to standard chemotherapy. For those patients with a positive site of disease that is poorly visualized on a scan, it can be per PI discretion to repeat the scan or proceed with enrollment without a recent scan.
  • HR-NB (as defined above) and in 1) first CR at ≥ 6 months from initiation of immunotherapy using anti-GD2 antibody, or 2) second or subsequent CR (achieved after treatment for PD). CR is defined according to the International Neuroblastoma Response Criteria. Patients with positive MIBG scan but negative FDG-PET scan, and CR in BM, are eligible. For those patients with a positive MIBG scan, the negative FDG-PET scan can be per PI discretion to repeat within the 45 day window period prior to enrollment.
  • Patients with grade 3 toxicities or less using the Common Toxicity Criteria (Version 5.0) developed by the National Cancer Institute of the USA ( v5.0) related to hematologic, cardiac, neurological, pulmonary, renal, hepatic or gastrointestinal function as determined by blood tests or physical exam. Plus:

    • (ANC) ≥ 500/mcl
    • Absolute lymphocyte count ≥ 500/mcl
  • >21 and \<180 days between completion of systemic therapy and 1st vaccination.
  • A negative pregnancy test is required for patients with child-bearing capability
  • Signed indicating awareness of the nature of this program.

Exclusion criteria

Exclusion Criteria:

  • Patients with grade 4 hematologic, cardiac, neurological, pulmonary, renal, hepatic or gastrointestinal function as determined by blood tests or physical exam, using the Common Toxicity Criteria (Version 5.0) developed by the National Cancer Institute of the USA.
  • History of allergy to KLH, QS-21, OPT-821, or glucan
  • Prior treatment with this vaccine.
  • Active life-threatening infection requiring systemic therapy.
  • Inability to comply with protocol requirements.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Group 1

    Participants will receive oral β-glucan (40 mg/kg/day) for 14 days on, and 14 days off, beginning with vaccination #1 and continuing until vaccination #5 (\~20 weeks), then only one 14-day cycle with each of vaccinations #6-#10.

    Biological: OPT-821 (QS-21) · Dietary Supplement: oral β-glucan

  • Experimental
    Group 2

    Participants will receive oral β-glucan (40 mg/kg/day) for 14 days on, and 14 days off, beginning with vaccination #1 and continuing until vaccination #7 (\~52 weeks), then only one 14-day cycle with each of vaccinations #8-#10.

    Biological: OPT-821 (QS-21) · Dietary Supplement: oral β-glucan

Interventions

  • BiologicalOBI-821Studies of OBI-821OBI-821 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Comprised of the immunological adjuvant OPT-821 (QS-21)

  • Dietary supplementoral β-glucan

    Participants will be randomized to receive this agent in two different schedules

06

What researchers measure

Primary outcomes

  1. Mean antibody titer in ng/ml of anti-GD2 IgG1 titer

    To determine the effect of oral β-glucan schedule on anti-GD2 antibody titers among patients who are in first or second (or later) CR, i.e., have no evidence of neuroblastoma by standard studies.

    Time frame: up to 32 weeks

07

Study locations

7 of 7 sites recruiting
  • Memorial Sloan Kettering at Basking Ridge (Consent only)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Brian Kushner, MD · Contact833-675-5491
  • Memorial Sloan Kettering Monmouth (Consent Only)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Brian Kushner, MD · Contact833-675-5491
  • Memorial Sloan Kettering Bergen (Consent Only)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Brian Kushner, MD · Contact833-675-5491
  • Memorial Sloan Kettering Suffolk-Commack (Consent only)
    Commack, New York 11725, United States
    Recruiting
    • Brian Kushner, MD · Contact833-675-5491
  • Memorial Sloan Kettering Westchester (Consent only)
    Harrison, New York 10604, United States
    Recruiting
    • Brian Kushner, MD · Contact833-675-5491
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
    Recruiting
    • Brian Kushner, MD · Contact833-675-5491
  • Memorial Sloan Kettering Nassau (Consent Only)
    Uniondale, New York 11553, United States
    Recruiting
    • Brian Kushner, MD · Contact833-675-5491
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Mar 2027, 42 months after the start.

Of 62 non-industry phase 2 interventional studies under Neuroblastoma, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 99. This study's planned 42 months is below that.

Counting every sponsor, half of 67 studies reached it within 74 months; a quarter within 52 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2023
First posted
Sep 28, 2023
StartActual
Sep 21, 2023
Primary completionEst.
Mar 21, 2027
CompletionEst.
Mar 21, 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
94→100
Oct 14, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedHR-NB as defined by risk-related treatment guidelines and international criteria,102 i.e., metastatic/non-localized disease with MYCN amplification (any age), metastatic disease >18 months old, MYCN-amplified localized disease (any age), or disease resistant to standard chemotherapy. For those patients with a positive site of disease that is poorly visualized on a scan, it can be per PI discretion to repeat the scan or proceed with enrollment without a recent scan.
Oct 14, 2026
Show all 2 updates
  1. Nov 9, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 14, 2026
    Enrollment 94→100
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedHR-NB as defined by risk-related treatment guidelines and international criteria,102 i.e., metastatic/non-localized disease with MYCN amplification (any age), metastatic disease >18 months old, MYCN-amplified localized disease (any age), or disease resistant to standard chemotherapy. For those patients with a positive site of disease that is poorly visualized on a scan, it can be per PI discretion to repeat the scan or proceed with enrollment without a recent scan.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06057948
Responsible party
Sponsor
First posted
Sep 28, 2023
Start date
Sep 21, 2023
Primary completion
Mar 21, 2027 (estimated)
Completion
Mar 21, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Brian Kushner, MD
Contact
kushnerb@MSKCC.ORG
1-833-MSK-KIDS
Fiorella Iglasias Cardenas, MD, MS
Contact
iglesiaf@mskcc.org
1-833-MSK-KIDS
Brian Kushner, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: OBI-821

Start the discussion